E-scape Bio: Funding, Investors & Team (Oct 2026)
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
E-scape Bio has raised $73.0M across 1 funding round on record, the most recent an undisclosed round of $73.0M announced in Sep 2020.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
E-scape Bio Company Profile and Key Stats
Latest funding round on record: Sep 2020.
E-scape Bio Funding Rounds
E-scape Bio Founders and Leadership Team
No contact details are on record for this team yet.
E-scape Bio Funding Compared to Other Biotechnology Startups
E-scape Bio's latest round of $73.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like E-scape Bio in Biotechnology and South San Francisco
Companies Similar to E-scape Bio
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
E-scape Bio Funding FAQs
What does E-scape Bio do?
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinson’s disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
How much funding has E-scape Bio raised?
E-scape Bio has raised $73.0M across 1 round on record. The most recent is an undisclosed round of $73.0M announced in Sep 2020.
When did E-scape Bio last raise funding?
E-scape Bio's most recent funding round on record is an undisclosed round of $73.0M, announced in Sep 2020.
Who is the CEO of E-scape Bio?
Julie Smith is listed as CEO at E-scape Bio.
Where is E-scape Bio headquartered?
E-scape Bio is based in South San Francisco, California, United States.
How many employees does E-scape Bio have?
E-scape Bio is in the 11-50 employee band.
How does E-scape Bio's funding compare to other Biotechnology startups?
E-scape Bio's latest round of $73.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's E-scape Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for E-scape Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.